Serum copper in ovarian carcinoma
β Scribed by Allan J. Jacobs; Gara M. Sommers; Janice H. Axelrod; Andrew E. Galakatos; Ming-Shian Kao; H. Marvin Camel
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 256 KB
- Volume
- 61
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
The serum copper and CA 125 levels of 31 patients with epithelial ovarian carcinoma were determined. Serum copper was elevated in seven patients and CA 125 was elevated in 22 patients. A rise in serum CA 125 always was associated with disease progression. In comparison, serum copper fluctuation did not correlate with the natural history of the malignancy. We concluded that serum copper determination has no use in epithelial ovarian carcinoma management.
Cancer 61:
π SIMILAR VOLUMES
## BACKGROUND. Accumulation of mutated p53 in malignant cells can lead to the generation of anti-p53 autoantibodies in the serum and other body fluids of cancer patients. This retrospective study was performed to evaluate the prognostic significance of preoperative serum and ascitic anti-p53 antibo
The appendix was identified as the only site of extrapelvic metastatic ovarian carcinoma at the time of primary surgical staging. Isolated appendiceal metastasis has not been previously reported in comprehensively staged early stage ovarian carcinoma. Routine appendectomy during surgical staging of